Get started
Author

Rachel Perret

Observed names: R PERRET, R. Perret
Observed institutions: Malaghan Institute of Medical Research, University of Washington, Fred Hutch Cancer Center, Ludwig Cancer Research, Ludwig Cancer Research, University of Lausanne
ORCID: 0000-0003-1225-5097
Observed ORCID: 0000-0003-1225-5097
OpenAlex ID: A5087604368
MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer
2013 · Jan C. Dudda, Bruno Salaun, et al. · Immunity · 304
Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity
2013 · Rachel Perret, Sophie R. Sierro, et al. · Cancer Research · 85
Combination of lentivector immunization and low‐dose chemotherapy or PD‐1/PD‐L1 blocking primes self‐reactive T cells and induces anti‐tumor immunity
2011 · Sophie R. Sierro, Alena Donda, et al. · European Journal of Immunology · 75
PDF
Memory T cells in cancer immunotherapy: which CD8+ T‐cell population provides the best protection against tumours?
2008 · R. Perret, F Ronchese · Tissue Antigens · 57
T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells
2021 · Yasmin Nouri, Robert Weinkove, et al. · Journal for ImmunoTherapy of Cancer · 54
PDF
Effector lymphoid tissue and its crucial role in protective immunity
2005 · N VANPANHUYS, R PERRET, et al. · Trends in Immunology · 43
Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response
2008 · Matthew Peacey, Sarah Wilson, et al. · Vaccine · 42
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
2012 · Stéphanie Corgnac, Rachel Perret, et al. · Cancer Immunology Immunotherapy · 36
PDF
Cancer Immunotherapy Principles and Practice
2017 · Lisa H. Butterfield, Howard L. Kaufman, et al. · Springer Publishing Company eBooks · 28
Dendritic Cells Treated with Lipopolysaccharide Up-Regulate Serine Protease Inhibitor 6 and Remain Sensitive to Killing by Cytotoxic T Lymphocytes In Vivo
2008 · Kate A Andrew, Helen M A Simkins, et al. · The Journal of Immunology · 26
PDF
iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine
2014 · Stéphanie Corgnac, Rachel Perret, et al. · Journal for ImmunoTherapy of Cancer · 21
Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines
2011 · Nathaly Castro-Díaz, Bruno Salaun, et al. · Vaccine · 19
Effector CD8+ T cells activated in vitro confer immediate and long‐term tumor protection in vivo
2008 · Rachel Perret, Franca Ronchese · European Journal of Immunology · 16
PDF
Tuning CAR T-cell therapies for efficacy and reduced toxicity
2024 · Danielle Blud, Patricia Rubio-Reyes, et al. · Seminars in Hematology · 13
Jurkat T-cell lines exhibit marked genomic instability affecting karyotype, mutational profile, gene expression, immunophenotype and function
2025 · Andrew Wilson, Nathaniel Dasyam, et al. · Scientific Reports · 9
PDF
An In Vitro Model to Assess CRS Potential of CAR T Cells Using a Tumor Cell Line and Autologous Monocytes
2023 · Yasmin Nouri, Robert Weinkove, et al. · Current Protocols · 9
PDF
Inefficient boosting of antitumor CD8+T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions
2012 · Joel Zhi-Iong Ma, Jianping Yang, et al. · OncoImmunology · 8
PDF
A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE)
2023 · Robert Weinkove, Philip George, et al. · Blood · 6
Peptide and Protein-Based Cancer Vaccines
2012 · Marion Braun, Rachel Perret, et al. · Springer eBooks · 5
A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)
2024 · Robert Weinkove, Philip George, et al. · Blood · 3
PDF
Magnetic selection for consistent cellular starting material in autologous cell therapy manufacture
2022 · Rachel Perret, Kenneth Olsen · Cell and Gene Therapy Insights · 2
PDF
Expanding the scope of WT1- and cyclin A1-specific TCR gene therapy for AML and other cancers
2016 · Rachel Perret, Karine Valliant-Saunders, et al. · The Journal of Immunology · 2
Abstract IA01: Engineering T cell responses to tumors: Taking the immune system where no responses have gone before
2016 · Philip D. Greenberg, Kristin G. Anderson, et al. · Cancer Immunology Research · 1
Analysis of Tumor-infiltrating Lymphocytes Following CD45 Enrichment
2014 · Rachel Perret, Sophie Sierro, et al. · BIO-PROTOCOL · 1
PDF
Chimeric antigen receptor T-cell transgene identity, site and methylation analysis via long-read sequencing
2026 · Nathaniel Dasyam, David Eccles, et al. · Blood Immunology & Cellular Therapy
Works count: 50
Citation count: 865
H-index: 13
I10-index: 14
Year
Topic
Type